Archive: 09/11/2015

Sorafenib modestly increases progression-free survival

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), ...

The boy who cried wolf: Drug alerts in the ER

To prevent a single adverse drug event, one commercial electronic health record opioid warning system fired off 123 unnecessary and clinically inconsequential alerts, according to the results of a new study published online ...

page 3 from 14